Randomized Clinical Trials in Colon and Rectal Cancer

Atif Iqbal; Thomas J George

doi:10.1016/j.soc.2017.05.008

Randomized Clinical Trials in Colon and Rectal Cancer

Surg Oncol Clin N Am. 2017 Oct;26(4):689-704. doi: 10.1016/j.soc.2017.05.008. Epub 2017 Aug 18.

Authors

Atif Iqbal¹, Thomas J George²

Affiliations

¹ Department of Surgery, University of Florida, 1600 Southwest Archer Road, PO Box 100106, Gainesville, FL 32610-0019, USA.
² Department of Medicine, University of Florida, 1600 Southwest Archer Road, PO Box 100278, Gainesville, FL 32610-0278, USA. Electronic address: Thom.George@medicine.ufl.edu.

PMID: 28923225
DOI: 10.1016/j.soc.2017.05.008

Abstract

Surgery remains the mainstay of treatment for colon and rectal cancers. Colon cancer outcomes have improved with laparoscopic techniques, enhanced recovery pathways, and adjuvant chemotherapy. Adjuvant 5-fluorouracil with or without oxaliplatin in stage III and possibly high-risk stage II colon cancer is associated with improved survival. Multimodality management of rectal cancer continues to evolve; total mesorectal excision is the cornerstone. Oncologic results do not support the use of laparoscopic resection in rectal cancer. Preoperative short- or long-course radiation for stage II or III rectal cancer is the standard of care. Long course chemoradiation is recommended for bulky tumors.

Keywords: Adjuvant; Chemotherapy; Colon cancer; Colorectal cancer; Neoadjuvant; Radiation; Rectal cancer; Surgery.

Publication types

Review

MeSH terms

Chemotherapy, Adjuvant*
Colonic Neoplasms / pathology
Colonic Neoplasms / therapy*
Fluorouracil / therapeutic use
Humans
Neoadjuvant Therapy*
Randomized Controlled Trials as Topic*
Rectal Neoplasms / pathology
Rectal Neoplasms / therapy*
Treatment Outcome

Substances

Fluorouracil